Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi.

Slides:

Advertisements

Similar presentations

Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost? Yolande Lievens, PhD, Caroline Obyn, MSc, Anne-Sophie Mertens, MSc, Dries.

Advertisements

Jeffrey Bradley, MD Journal of Thoracic Oncology

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

Clinical Value of Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Differentiation of Malignant Mesothelioma from Asbestos-Related.

Gingival Metastasis as First Sign of Multiorgan Dissemination of Epithelioid Malignant Mesothelioma Andrea Billè, Marco Platania, Giuseppe Pelosi, Barbara.

Dosimetric Consequences of 3D Versus 4D PET/CT for Target Delineation of Lung Stereotactic Radiotherapy Shankar Siva, MBBS, FRANZCR, Brent Chesson, BAppSc.

18F-Sodium Fluoride PET–CT for the Assessment of Brain Metastasis from Lung Adenocarcinoma Stefania Gori, MD, Alessandro Inno, MD, PhD, Gianluigi Lunardi,

Salvage Stereotactic Ablative Irradiation for Isolated Postsurgical Local Recurrence of Lung Cancer Atsuya Takeda, MD, PhD, Naoko Sanuki, MD, Takahisa.

Rash in a Patient Treated with Pemetrexed for Relapsed Non-small Cell Lung Cancer Isabelle Declercq, MD, Yolande Lievens, MD, PhD, Eric Verbeken, MD,

One in every 14 patients with early-stage lung cancer is not being treated! Benny Weksler, MD, MBA The Journal of Thoracic and Cardiovascular Surgery

Disparities in Treatment of Patients with Inoperable Stage I Non–Small Cell Lung Cancer: A Population-Based Analysis Matthew Koshy, MD, Renuka Malik,

Michael C. Roach, MD, Gregory M. M. Videtic, MD, CM, FRCPC, Jeffrey D

Severe Local Toxicity after Lung Stereotactic Body Radiation Therapy: Lesional Abscess Leading to Bronchocutaneous Fistula Requiring Surgical Marsupialization

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Interpretation Criteria for Assessment of Antibiotic Treatment Response in Pyogenic.

Nivolumab Enhances the Inflammation of the Irradiation Field in Advanced Non–Small Cell Lung Cancer Hiromi Furuta, MD, PhD, Tatsuya Yoshida, MD, PhD,

MET-Mutated NSCLC with Major Response to Crizotinib

Salvage Lung Resection After Definitive Radiation (>59 Gy) for Non-Small Cell Lung Cancer: Surgical and Oncologic Outcomes Julie E. Bauman, MD, Michael.

Electronic Updates for JTO Readers

Treatment and Prognosis of Isolated Local Relapse after Stereotactic Body Radiotherapy for Clinical Stage I Non-Small-Cell Lung Cancer Masatsugu Hamaji,

Intensity-Modulated Radiotherapy for Lung Cancer: Current Status and Future Developments Clara Chan, MD, Stephanie Lang, MSc, Carl Rowbottom, PhD, Matthias.

Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non–Small-Cell Lung Cancer: What We Have Learned Joe Y. Chang, MD, PhD, Andrea Bezjak,

Radiological Changes After Stereotactic Radiotherapy for Stage I Lung Cancer Max Dahele, MBChB, MSc, David Palma, MD, Frank Lagerwaard, MD, PhD, Ben Slotman,

Maximum Standardized Uptake Value on FDG-PET Is a Strong Predictor of Overall and Disease-Free Survival for Non–Small-Cell Lung Cancer Patients after.

Central versus Peripheral Tumor Location: Influence on Survival, Local Control, and Toxicity Following Stereotactic Body Radiotherapy for Primary Non–Small-Cell.

A Severe Photosensitivity Dermatitis Caused by Crizotinib

Follow-Up of Patients after Stereotactic Radiation for Lung Cancer: A Primer for the Nonradiation Oncologist Kitty Huang, MSc, MDCM, David A. Palma,

Toxicities of Organs at Risk in the Mediastinal and Hilar Regions Following Stereotactic Body Radiotherapy for Centrally Located Lung Tumors Shuichi.

Kiran Devisetty, MD, Joseph K. Salama, MD Journal of Thoracic Oncology

Effective Treatment with Icotinib in Primary Adenoid Cystic Carcinoma of the Lung with Liver Metastasis Zhengbo Song, MD, Wei Wu, MD, Yiping Zhang, MD

Preliminary Report of Late Recurrences, at 5 Years or More, after Stereotactic Body Radiation Therapy for Non-small Cell Lung Cancer Yukinori Matsuo,

A New KIT Gene Mutation in Thymic Cancer and a Promising Response to Imatinib Sung Hee Lim, MD, Ji-Yun Lee, MD, Jong-Mu Sun, MD, PhD, Kyoung-Mee Kim,

Chest Wall Pain and Rib Fracture after Stereotactic Radiotherapy for Peripheral Non- small Cell Lung Cancer Jon-Paul J. Voroney, PhD, MD, Andrew Hope,

Stereotactic Body Radiotherapy for Lung Cancer: How Much Does it Really Cost? Yolande Lievens, PhD, Caroline Obyn, MSc, Anne-Sophie Mertens, MSc, Dries.

Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Interpretation Criteria for Assessment of Antibiotic Treatment Response in Pyogenic.

Incidence and Risk Factors for Chest Wall Toxicity After Risk-Adapted Stereotactic Radiotherapy for Early-Stage Lung Cancer Eva M. Bongers, MD, Cornelis.

Elderly Former Smoker with HRAS Mutant Non–Small-Cell Lung Cancer

Patterns of Disease Recurrence after SABR for Early Stage Non–Small-Cell Lung Cancer: Optimizing Follow-Up Schedules for Salvage Therapy Naomi E. Verstegen,

Stereotactic Ablative Radiation Therapy for Lung Oligometastases: Predictive Parameters of Early Response by 18FDG-PET/CT Rosario Mazzola, MD, Alba Fiorentino,

A Case of Pleural Epithelioid Sarcoma of Proximal Type Presenting as Malignant Pleural Mesothelioma Gitte Anna Madsen, MD, Torben Riis Rasmussen, MD,

PET/CT Findings for Bone Marrow Carcinosis Because of Lung Adenocarcinoma Keisuke Watanabe, MD, Masaharu Shinkai, MD, PhD, Kenjiro Nagai, MD, Nobuhiro.

Elizabeth Cathcart-Rake, MD, Ariel Lopez-Chavez, MD, MS

Steve R. Siegal, MD, John G. Hunter, MD, James P. Dolan, MD, MCR

Positron Emission Tomography 18F-Fluorodeoxyglucose Uptake and Prognosis in Patients with Surgically Treated, Stage I Non-small Cell Lung Cancer: A Systematic.

Stereotactic Body Radiotherapy in Patients with Previous Pneumonectomy: Safety and Efficacy Robert Thompson, MD, Meredith Giuliani, MBBS, Mei Ling Yap,

Value of Combined Interpretation of Computed Tomography Response and Positron Emission Tomography Response for Prediction of Prognosis After Neoadjuvant.

Acute intramural hematoma of the aorta as a cause of positive fluorodeoxyglucose positron emission tomography/computed tomography Alex Ryan, MD, Barry.

A Case of Nontuberculous Mycobacteria Highly Suspected as Lung Cancer Invading the Aortic Arch Tadashi Umehara, MD, Masaya Aoki, MD, PhD, Aya Harada,

Osimertinib for Epidermal Growth Factor Receptor Mutation–Positive Lung Adenocarcinoma That Transformed to T790M-Positive Squamous Cell Carcinoma Naoyuki.

Mirror Mirror on the Wall, Who Is the Fairest of Them All

Osteoblastic Bone Flare on F18-FDG PET in Non-small Cell Lung Cancer (NSCLC) Patients Receiving Bevacizumab in Addition to Standard Chemotherapy Yelena.

Nicholas Trakul, MD, PhD, Jeremy P

Jeffrey Bradley, MD Journal of Thoracic Oncology

Iris Metastasis from Small-Cell Lung Cancer

Nicholas W. Choong, MD, Robert S. Hellman, MD

Beware of the “Bronchocele,” Particularly in Patients with a History or Risk Factors for a Mucinous Carcinoma: A Response to the Article “Resection of.

Gaurav Marwaha, MD, Kevin L. Stephans, MD, Neil M

Primary Tumor Standardized Uptake Value Measured on F18-Fluorodeoxyglucose Positron Emission Tomography Is of Prediction Value for Survival and Local.

Antiangiogenesis Induced Tumor Cavitation in Lung Cancer

Pulmonary Atelectasis after Stereotactic Ablative Radiotherapy for a Central Lung Tumor Sashendra Senthi, MBChB, FRANZCR, Eric F Ullmann, MD, Suresh.

Pitfalls in Oncology: Osteoblastic Response Mimicking Bone Progression during Ceritinib Treatment in ALK-Rearranged NSCLC Francesco Gelsomino, MD, Valentina.

S-1 Treatment for Chemorefractory Thymic Carcinoma

Management of Mediastinal Relapse after Treatment with Stereotactic Body Radiotherapy or Accelerated Hypofractionated Radiotherapy for Stage I/II Non–Small-

Successful AZD9291 Therapy Based on Circulating T790M

Todd J. Carpenter, MD, Kenneth E. Rosenzweig, MD

Size matters: A comparison of T1 and T2 peripheral non–small-cell lung cancers treated with stereotactic body radiation therapy (SBRT) Neal E. Dunlap,

APLCC POSTER SESSION 2 - WEDNESDAY, NOVEMBER 28

Lack of FDG Uptake in Small Cell Carcinoma Associated with ANNA-1 Positive Paraneoplastic Autonomic Neuropathy Matthew S. Block, MD, PhD, Robert Vassallo,

Super Scan Using Positron Emission Tomography in Lung Cancer Patients

Patterns-of-Care for Thoracic Stereotactic Body Radiotherapy among Practicing Radiation Oncologists in the United States Megan E. Daly, MD, Julian R.

Ana Luque, MD, Edurne Arriola, MD, PhD Journal of Thoracic Oncology

Presentation transcript:

Dose-Escalated Stereotactic Body Radiotherapy (SBRT) as a Salvage Treatment for Two Cases with Relapsed Peripheral Lung Cancer After Initial SBRT Shuichi Nishimura, MD, Atsuya Takeda, MD, PhD, Naoko Sanuki, MD, PhD, Sachiko Yoshida, MD, PhD, Naoyuki Shigematsu, MD, PhD Journal of Thoracic Oncology Volume 10, Issue 8, Pages e69-e71 (August 2015) DOI: 10.1097/JTO.0000000000000543 Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Case 1: A, [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) before the initial stereotactic body radiotherapy (SBRT). The maximum standardized uptake value (SUVmax) was 3.3. B, Planning CT with dose distribution curves of the initial SBRT. A prescribed dose of 50 Gy was delivered in five fractions, with isodose lines from outer to inner representing 20, 30, 40, 50, and 60 Gy. C, 18F-FDG-PET/CT at 24 months after the initial SBRT (SUVmax: 6.7). D, Planning CT with dose distribution curves of salvage SBRT. A prescribed dose of 60 Gy was delivered in five fractions, with isodose lines from outer to inner representing 20, 40, 60, 80, and 90 Gy. E, 18F-FDG-PET/CT (SUVmax: 3.4) and (F) plain CT obtained 12 months after salvage SBRT. Journal of Thoracic Oncology 2015 10, e69-e71DOI: (10.1097/JTO.0000000000000543) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Case 2: A, [18F]-fluorodeoxyglucose-positron emission tomography/computed tomography (18F-FDG-PET/CT) before the initial stereotactic body radiotherapy (SBRT). The maximum standardized uptake value (SUVmax) was 9.0. B, Planning CT with dose distribution curves of the initial SBRT. A prescribed dose of 50 Gy was delivered in five fractions, with isodose lines from outer to inner representing 20, 30, 40, 50, and 60 Gy. C, 18F-FDG-PET/CT at 10 months after the initial SBRT (SUVmax: 4.4). D, Planning CT with dose distribution curves of salvage SBRT. A prescribed dose of 60 Gy was delivered in five fractions, with isodose lines from outer to inner representing 20, 40, 60, 80, and 90 Gy. E, 18F-FDG-PET/CT (SUVmax: 2.1) and (F) plain CT obtained 36 months after salvage SBRT. Journal of Thoracic Oncology 2015 10, e69-e71DOI: (10.1097/JTO.0000000000000543) Copyright © 2015 International Association for the Study of Lung Cancer Terms and Conditions